✅ What You’re Getting

Note: FDA-approved tirzepatide products are supplied in fixed-dose pens/vials (e.g., 2.5–15 mg per weekly dose). 1

🧠 Mechanism of Action (How It Works)

• Dual receptor activation (GIP + GLP-1): Tirzepatide selectively binds and activates both receptors involved in appetite and metabolic control. 2
• Appetite & calorie intake reduction: Brain pathways involved in satiety are activated, typically lowering overall calorie intake over time. 3
• Glucose-dependent insulin support: Increases insulin secretion when glucose is elevated (reducing risk compared with non–glucose-dependent secretagogues), and reduces glucagon secretion. 4
• Improved insulin sensitivity: Clinical pharmacology data show improved insulin sensitivity after sustained use. 5
• Delayed gastric emptying: Slows stomach emptying most strongly after early doses; this can reduce post-meal glucose spikes and influence absorption of oral medications. 6

📅 Dosing Protocol (Clinical Reference — Once Weekly Titration)

Below is the label-referenced titration approach used to reduce GI side effects (nausea, diarrhea, vomiting, constipation). 7
This is provided for education—individual dosing should be determined by a licensed clinician.

1. Weeks 1–4: Start at 2.5 mg once weekly (initiation dose; not a maintenance dose). 8
2. Week 5+: Increase to 5 mg once weekly. 9
3. Further escalation (as tolerated): Increase by 2.5 mg increments, staying at each dose for at least 4 weeks before increasing again. 10
4. Common maintenance range: 5 mg, 10 mg, or 15 mg once weekly (maximum recommended is 15 mg once weekly). 11

🥗 Dietary Recommendations (Maximize Results + Reduce Side Effects)

• Protein-forward meals: Aim for a protein target you can consistently hit daily (helps preserve lean mass while weight drops).
• Small-to-moderate meals: Overeating can worsen nausea/reflux due to slower gastric emptying. 13
• Limit high-fat “heavy” meals near dose day if you’re prone to GI effects (fat slows gastric emptying further and can amplify symptoms).
• Hydration + electrolytes: Especially important if appetite drops significantly or if diarrhea/vomiting occur (volume depletion risk). 14
• Fiber, but not a “fiber bomb” overnight: Gradually increase fiber (vegetables, berries, oats, psyllium) to support regularity.
• Carb strategy: Many do well with higher-fiber, lower-glycemic carbs (potatoes/rice can still fit—portion and timing matter).
• Resistance training 2–4x/week: Helps maintain muscle while dieting and improves insulin sensitivity.

⚠️ Who Should NOT Use Tirzepatide (Contraindications & High-Risk Situations)

The following are key restrictions and major cautions drawn from prescribing information for tirzepatide products. 15

🚫 Absolute contraindications

• Personal or family history of Medullary Thyroid Carcinoma (MTC)
• Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
• Known serious hypersensitivity to tirzepatide or excipients (e.g., anaphylaxis/angioedema history)

These are directly listed as contraindications. 16

⚠️ Use extreme caution / clinician must evaluate

• History of pancreatitis or symptoms suggestive of pancreatitis (severe abdominal pain radiating to back, +/- vomiting). 17
• Severe gastrointestinal disease (tirzepatide can cause severe GI adverse reactions). 18
• Gallbladder disease risk (acute gallbladder events are a known warning category). 19
• Diabetic retinopathy history (if T2D): rapid glucose improvement can temporarily worsen retinopathy; monitoring is advised. 20
• Kidney issues + dehydration risk: volume depletion from GI side effects can precipitate acute kidney injury; monitor renal function if symptoms occur. 21
• Depression / suicidal ideation history: weight-management labeling advises monitoring mood changes; avoid in active suicidal ideation or prior attempts (per labeling). 22
• Upcoming surgery/anesthesia: delayed gastric emptying has been associated with rare aspiration reports under anesthesia/deep sedation—patients should inform providers. 23
• Pregnancy: discontinue when pregnancy is recognized; weight loss is not recommended during pregnancy (label warning). 24

💊 Medications & Substances That Should NOT Be Combined (or Require Adjustment)

• Other GLP-1 receptor agonists (and other tirzepatide-containing products): coadministration is not recommended in labeling. 25
• Insulin or insulin secretagogues (e.g., sulfonylureas): increased hypoglycemia risk—dose reduction may be required and glucose monitoring is important. 26
• Oral medications with narrow therapeutic index (example given: warfarin): delayed gastric emptying can impact absorption—monitor closely. 27
• Oral hormonal contraceptives: may be less effective during initiation and after each dose escalation; labeling advises switching to non-oral contraception or adding barrier protection for 4 weeks after starting and after each dose increase. 28

😵 Common Side Effects (What Most People Notice First)

The most common effects are gastrointestinal and tend to be dose-related and most noticeable early in titration. 29

• Nausea
• Diarrhea
• Vomiting
• Constipation
• Abdominal pain / dyspepsia
• Injection site reactions, fatigue (reported in trials)

🧾 Important Notice

This description is provided for general educational purposes and is not medical advice.
Tirzepatide is a prescription medication in FDA-approved forms, and suitability depends on your medical history, labs, and current medications.
Always consult a licensed clinician before starting or combining any metabolic therapy—especially if you have diabetes, take glucose-lowering meds,
have thyroid cancer risk factors, are pregnant/trying to conceive, or have significant GI or gallbladder issues. 31